Immatics Announces Third Quarter 2022 Financial Results and Business Update
17 nov. 2022 07h00 HE
|
https://immatics.com/
Interim clinical update on ACTengine® IMA203 TCR-T monotherapy targeting PRAME demonstrated high confirmed objective response rate (cORR) of 50% (6/12) at or above target dose across Phase 1a and...
Immatics veröffentlicht Ergebnisse des dritten Quartals 2022 sowie ein Update zur Geschäftsentwicklung
17 nov. 2022 07h00 HE
|
Immatics N.V.
Klinisches Daten-Update zu ACTengine® IMA203 TCR-T-Monotherapie gegen die Zielstruktur PRAME zeigt hohe bestätigte objektive Ansprechrate (confirmed objective response rate, cORR) von 50 % (6/12) bei...
Evaxion announces promising results from Phase 1/2a clinical trial of personalized DNA cancer immunotherapy EVX-02
17 nov. 2022 06h59 HE
|
Evaxion Biotech
COPENHAGEN, Denmark, Nov. 17, 2022 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of...
$32.4 Bn Cell Therapy Instruments Market to Exhibit CAGR of 13.2% by 2027, Deep Dive Analysis of Key Players and Growth Opportunities
15 nov. 2022 08h17 HE
|
The Insight Partners
New York, Nov. 15, 2022 (GLOBE NEWSWIRE) -- According to The Insight Partners latest study on "Cell Therapy Instrument Market Size, Share, Growth, Trends and Forecast to 2027 – COVID-19 Impact and...
BriaCell CEO Discusses Positive Clinical Results of its Breast Cancer Immunotherapy Treatment in an Audio Interview with SmallCapVoice.com
15 nov. 2022 08h00 HE
|
Briacell Therapeutics Corp.
AUSTIN, Texas, Nov. 15, 2022 (GLOBE NEWSWIRE) -- SmallCapVoice.com Inc. (“SCV”) announces the availability of a new audio interview with Dr. Bill Williams, CEO of BriaCell Therapeutics Corp....
ImmunOs Therapeutics´ Lead Program Shows Strong Anti-Tumor Activity In Vivo and In Vitro
15 nov. 2022 04h00 HE
|
AKAMPION
- Promising data presented at Protein and Antibody Engineering Summit (PEGS) - Multi-functional agent targeting three immune checkpoint receptors - Potential as mono- and combination therapy for...
Cancer Gene Therapy Market Report 2022: High Growth in the Pharmaceutical Industry Driving Sector
14 nov. 2022 08h21 HE
|
Research and Markets
Dublin, Nov. 14, 2022 (GLOBE NEWSWIRE) -- The "Cancer Gene Therapy Market Size, Share & Trends Analysis Report by Therapy (Oncolytic Virotherapy, Gene Induced Immunotherapy, Gene Transfer), by...
PDS Biotech Reports Third Quarter 2022 Financial Results and Provides Business Update
14 nov. 2022 07h30 HE
|
PDS Biotechnology Corporation
Announced preliminary PDS0101 efficacy and safety data for Phase 2 clinical studies led by The University of Texas MD Anderson Cancer Center (IMMUNOCERV) and The National Cancer Institute at SITC...
PDS Biotech Announces 100% Clinical Response in Cervical Cancer Patients in Preliminary Data from IMMUNOCERV Phase 2 Clinical Trial
14 nov. 2022 07h00 HE
|
PDS Biotechnology Corporation
In the trial studying the combination of PDS0101 with standard-of-care chemoradiotherapy: 100% (9/9) showed clinical response (>60% tumor shrinkage at mid-point evaluation)89% (8/9) had no...
BiondVax Announces Plan to Implement ADS Ratio Change
10 nov. 2022 16h00 HE
|
BiondVax Pharmaceuticals Ltd.
JERUSALEM, Nov. 10, 2022 (GLOBE NEWSWIRE) -- via InvestorWire -- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV) (“BiondVax”), a biotechnology company focused on developing, manufacturing, and...